Ask about this productRelated genes to: AKT1 antibody
- Gene:
- AKT1 NIH gene
- Name:
- AKT serine/threonine kinase 1
- Previous symbol:
- -
- Synonyms:
- RAC, PKB, PRKBA, AKT
- Chromosome:
- 14q32.33
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: AKT1 antibody
Related articles to: AKT1 antibody
- Haizao Yuhu Decoction (HYD), a classic Traditional Chinese Medicine (TCM) formula, is used to treat Yingbing, which corresponds to goiter in modern medicine. Although HYD has been extensively studied for goiter, its specific active components and the underlying mechanisms of action remain to be fully elucidated. This study investigated the effects and mechanisms of HYD in goiter using untargeted LC-MS metabolomics (comparing HYD decoction and HYD-containing serum), network pharmacology for target prediction, and in vitro validation with a TSHR human monoclonal antibody M22 (TSHR hMAb M22)-induced thyroid cell proliferation model, followed by Western blotting to verify key pathway proteins. The comparison of metabolomic profiles between HYD decoction and HYD-containing serum revealed that 2091 metabolites (90.05%) were downregulated, while 231 were upregulated in medicated serum. Network pharmacology predicted targets including AKT1, PIK3CA, ESR2, ESR1, and TP53. HYD-containing serum exhibited pro-apoptotic effects on the cell proliferation model. The underlying mechanism may primarily involve the upregulation of the p53/PUMA/p21 pathway, which subsequently affects caspase-3 activity. Furthermore, the action of HYD may involve non-p53 multiple signaling pathways. HYD may exert its effects by modulating multiple signaling pathways, including p53/PUMA/p21, leading to apoptosis in thyroid cells. - Source: PubMed
Liu XiaoqingLiao WenyongXu XiangnanWu MeijingZhang JiwenWu YinghaoChen ShaohongLiu HaiyanZhang ShujingXiu LinlinZhong Gansheng - To elucidate the mechanism of action of the - herb pair in treating coronary heart disease (CHD) through network pharmacology combined with molecular docking and experimental validation. Active ingredients and target proteins were retrieved from the Traditional Chinese Medicine Systems Pharmacology database. CHD-related targets were obtained from GeneCards and DrugBank. Overlapping targets were identified with a Venn diagram, and a protein-protein interaction network was built in STRING. Core targets were screened via topological analysis in Cytoscape 3.9.0. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were performed in Metascape. AutoDock Vina was used for molecular docking. , tumor necrosis factor (TNF)-α levels in HL-1 cells subjected to oxygen-glucose deprivation (OGD) were measured by ELISA, and the effect of mangiferin pretreatment on cell viability was assessed with a CCK-8 assay. Forty-one active ingredients and 207 putative targets were identified for the herbal pair, and 1843 CHD-related targets were collected; 67 overlapping therapeutic targets were obtained. Topological analysis yielded 27 core targets. GO terms were enriched in responses to lipopolysaccharide, toxic substances, and organic cyclic compounds; molecular functions included cytokine-receptor binding and transcription-factor binding; and cellular components were mainly membrane rafts and extracellular matrix. KEGG analysis highlighted the TNF, fluid-shear-stress, and NF-κB signaling pathways. Docking showed strong binding between key components and targets. experiments demonstrated that formononetin pretreatment significantly reduced OGD-induced TNF-α levels and improved HL-1 cell viability. The - combination herb pair exerts anti-CHD effects via multiple bioactive ingredients ( formononetin, quercetin, isorhamnetin, ginsenoside Rh2, kaempferol) by targeting TNF, AKT1, PTGS2, and JUN and modulating pathways including the TNF and NF-κB signaling pathways. - Source: PubMed
Publication date: 2026/04/23
Liu ZhipingChen JiaMeng TianweiWang BoyuLi ChengjiaLiu ChangxingWang Yingying - While mounting evidence points to a potential link between industrial aluminum exposure and neurodegenerative diseases like Alzheimer's disease (AD), the precise intervention strategies remain an area of active research. This study proposes a "multi-target synergy and dose threshold control" exploratory framework for evaluating crude oil (IPCO) in an aluminum-induced AD model. An integrated analytical approach employing GC-MS and network pharmacology was used to identify three candidate core components-(Z,Z)-9,12-octadecadienoic acid, Beta-amyrin, and 2,4-di-tert-butylphenol-that were computationally predicted to influence a network of 35 ad-related pathways (e.g., Calcium and PPAR signaling) via eight potential key targets (including , , and ). In vivo experiments revealed a dose-dependent modulation of AD-related pathology following IPCO intervention. The high-dose group showed the most marked improvements in several therapeutic markers, including reduced aluminum load, an anti-inflammatory shift in cytokine levels (elevated IL-10, decreased IL-4, IL-6, IL-1β, and TNF-α), and remodeling of the gut microbiota characterized by an increase in putative short-chain fatty acid (SCFA)-producing genera such as the and (). Paradoxically, this same high dose was associated with a decline in spatial cognitive performance. This biphasic effect may be preliminarily explained by a dual microbial mechanism: the inhibition of the pro-inflammatory associated alongside the expansion of taxa linked to a neuroprotective SCFA metabolic network. As one of the first studies to map these multi-dimensional "constituent-microbiota-neuroinflammation" interactions for IPCO, our findings highlight its complex, dose-sensitive bioactivity. Importantly, they underscore the critical need for subsequent pharmacokinetic and direct target engagement studies. - Source: PubMed
Publication date: 2026/04/20
Chang WeijieChen YaobingKan JianquanHuang XiufangLuo Kai - Zhenyuan Solid Drink (ZYSD) is a formulation consisting of 6 medicinal herbs that can be used as both food and medicinal materials in China. This comprehensive analysis aims to illuminate the potential therapeutic effects and underlying mechanisms of ZYSD in the context of ischemic myocardial infarction. Marker components in ZYSD were identified by high performance liquid chromatography (HPLC) through comparison with reference compounds. Isoproterenol (ISO)-induced rats were employed as the in vivo model of ischemic myocardial infarction. Subsequently, a multi-tiered approach integrating cardiac color Doppler ultrasound, cardiac enzyme marker analysis, inflammatory factor detection, gut microbiota profiling, network pharmacology, molecular docking, molecular dynamics (MD) simulation, and western blot analysis was employed to elucidate the effects and underlying mechanisms of ZYSD, with intervention in alleviating metoprolol tartrate as positive control. Ten compounds, derived from 6 medicinal plants, in ZYSD were identified as marker components for the quality control via HPLC. Animal studies confirmed the preventive and therapeutic efficacy of ZYSD against ischemic myocardial infarction, as evidenced by the improvement of cardiac function and the attenuation of inflammation and oxidative stress. Using network pharmacology and molecular docking, the active constituents including marker compounds of ZYSD exhibited strong binding affinity to their key targets, including AKT1 and NRF2. MD simulation further indicated the binding interaction between ZYSD components and AKT1. Western blot analysis results further verified that ZYSD regulates the TLR4/NF-κB pathway and PI3K/AKT1/NRF2 pathway. Collectively, our findings demonstrate that ZYSD mitigates inflammation and oxidative stress, potentially through the TLR4/NF-κB and PI3K/AKT1/NRF2 pathways, thereby providing a novel strategy for the prevention and treatment of ischemic myocardial infarction. - Source: PubMed
Publication date: 2026/04/19
Huang JiawenYu TianLi GuoyiNie KechaoLiu DonghuaMeng CongShen XiaolingFu LinchunLong LiangFu ZhuotaoDeng ZhitongHu Yingjie - Maxim (DrT) is a well-known traditional medicinal and edible plant with hepatoprotective effects. In this study, crude polysaccharides of DrT (DrTPs) were obtained using the water extraction-ethanol precipitation method. Autoimmune hepatitis (AIH) models of both mice and ALM12 cells were produced by ConA. The serum liver function indexes (AST and ALT) were examined by ELISA, and liver tissue pathological changes were observed by HE staining. The hepatoprotective mechanism of DrTP80 was explored by RNA sequencing and verified by detecting the protein expressions using Western blot. As a result, DrTP80 could significantly reduce AST and ALT levels in the injured liver and ALM12 cells. DrTP80 also obviously improved the hepatopathological changes in liver tissue induced by ConA. Furthermore, RNA sequencing detected significant differences in gene expression, and the functions of differential genes were focused on TNF and IL-17 signaling pathways. Based on these two signaling pathways, 13 differentially expressed genes (Vcam1, Atf6b, Akt1, Irf1, Map2k3, Lcn2, Hsp90ab1, Anapc5, Traf4, Fosl1, Jun, Cxcl5, Nfκbia) among NC, CRC, and FP groups were screened and verified by Western blot. In conclusion, our results demonstrated that DrTP80 can alleviate immune liver damage induced by ConA, and its hepatoprotective mechanism may be related to regulating TNF and IL-17 signaling pathways. Our findings indicated that DrTP80 could be exploited as a healthy food supplement for the treatment of immune liver injury. - Source: PubMed
Publication date: 2026/03/24
Guo MinWei SaixueCheng BiaobiaoLi Xiaodong